Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones

These cases suggest biological activity and support continued dose escalation for ovarian cancer patients who have no alternatives. We expect to report further clinical observations later this year. Our partnership with Moffitt—a leader in cellular immunotherapy—continues to be a vital asset in developing this novel technology. SAN JOSE, Calif., May 19, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of c ...